These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 29088896)

  • 21. Platinum-based chemotherapy in metastatic triple negative breast cancer: Experience of a tertiary referral centre in India.
    Maka VV; Panchal H; Shukla SN; Talati SS;
    Gulf J Oncolog; 2015 Jan; 1(17):52-7. PubMed ID: 25682453
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neoadjuvant chemotherapy in triple-negative breast cancer: A multicentric retrospective observational study in real-life setting.
    Gamucci T; Pizzuti L; Sperduti I; Mentuccia L; Vaccaro A; Moscetti L; Marchetti P; Carbognin L; Michelotti A; Iezzi L; Cassano A; Grassadonia A; Astone A; Botticelli A; Magnolfi E; Di Lauro L; Sergi D; Fuso P; Tinari N; Barba M; Maugeri-Saccà M; Landucci E; Conti F; Sanguineti G; De Tursi M; Iafrate G; Giordano A; Ciliberto G; Natoli C; Vici P
    J Cell Physiol; 2018 Mar; 233(3):2313-2323. PubMed ID: 28710865
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pathological complete response to neoadjuvant chemotherapy, but not the addition of carboplatin, is associated with improved survival in Chilean triple negative breast cancer patients: a report of real world data.
    Walbaum B; Acevedo F; Medina L; Bravo ML; Merino T; Camus M; Dominguez F; Mondaca S; Galindo H; Nervi B; Ibañez C; Madrid J; Muñiz S; Peña J; Koch É; Garrido M; Pinto MP; Sánchez C
    Ecancermedicalscience; 2021; 15():1178. PubMed ID: 33777171
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial.
    Cameron D; Brown J; Dent R; Jackisch C; Mackey J; Pivot X; Steger GG; Suter TM; Toi M; Parmar M; Laeufle R; Im YH; Romieu G; Harvey V; Lipatov O; Pienkowski T; Cottu P; Chan A; Im SA; Hall PS; Bubuteishvili-Pacaud L; Henschel V; Deurloo RJ; Pallaud C; Bell R
    Lancet Oncol; 2013 Sep; 14(10):933-42. PubMed ID: 23932548
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment outcomes and clinicopathologic characteristics of triple-negative breast cancer patients who received platinum-containing chemotherapy.
    Uhm JE; Park YH; Yi SY; Cho EY; Choi YL; Lee SJ; Park MJ; Lee SH; Jun HJ; Ahn JS; Kang WK; Park K; Im YH
    Int J Cancer; 2009 Mar; 124(6):1457-62. PubMed ID: 19065658
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The taxane-based chemotherapy triplet is superior to the doublet in one to nine node-positive but not node-negative triple-negative breast cancer: results from a retrospective analysis.
    Guo S; Shi Y; Lu S; He Y; Jin G; Zhang S; Li X
    J Cancer; 2020; 11(22):6653-6662. PubMed ID: 33046986
    [No Abstract]   [Full Text] [Related]  

  • 27. Current strategy for triple-negative breast cancer: appropriate combination of surgery, radiation, and chemotherapy.
    Yagata H; Kajiura Y; Yamauchi H
    Breast Cancer; 2011 Jul; 18(3):165-73. PubMed ID: 21290263
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Platinum-based chemotherapy in triple-negative breast cancer: A meta-analysis.
    Liu M; Mo QG; Wei CY; Qin QH; Huang Z; He J
    Oncol Lett; 2013 Mar; 5(3):983-991. PubMed ID: 23426861
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and efficacy of pegylated liposomal doxorubicin-based adjuvant chemotherapy in patients with stage I-III triple-negative breast cancer.
    Lien MY; Liu LC; Wang HC; Yeh MH; Chen CJ; Yeh SP; Bai LY; Liao YM; Lin CY; Hsieh CY; Lin CC; Li LY; Lin PH; Chiu CF
    Anticancer Res; 2014 Dec; 34(12):7319-26. PubMed ID: 25503167
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pathological complete response following cisplatin or carboplatin-based neoadjuvant chemotherapy for triple-negative breast cancer: A systematic review and meta-analysis.
    Vidra R; Nemes A; Vidrean A; Pintea S; Tintari S; Deac A; Ciuleanu T
    Exp Ther Med; 2022 Jan; 23(1):91. PubMed ID: 34934456
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The survival benefit of neoadjuvant chemotherapy and pCR among patients with advanced stage triple negative breast cancer.
    Biswas T; Efird JT; Prasad S; Jindal C; Walker PR
    Oncotarget; 2017 Dec; 8(68):112712-112719. PubMed ID: 29348858
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Significance of Tumor-Infiltrating Lymphocytes and the Expression of Topoisomerase IIα in the Prediction of the Clinical Outcome of Patients with Triple-Negative Breast Cancer after Taxane-Anthracycline-Based Neoadjuvant Chemotherapy.
    Rao N; Qiu J; Wu J; Zeng H; Su F; Qiu K; Wu J; Yao H
    Chemotherapy; 2017; 62(4):246-255. PubMed ID: 28472798
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tailoring adjuvant chemotherapy regimens for patients with triple negative breast cancer.
    Stover DG; Winer EP
    Breast; 2015 Nov; 24 Suppl 2():S132-5. PubMed ID: 26255198
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HAGE in Triple-Negative Breast Cancer Is a Novel Prognostic, Predictive, and Actionable Biomarker: A Transcriptomic and Protein Expression Analysis.
    Abdel-Fatah TM; McArdle SE; Agarwal D; Moseley PM; Green AR; Ball GR; Pockley AG; Ellis IO; Rees RC; Chan SY
    Clin Cancer Res; 2016 Feb; 22(4):905-14. PubMed ID: 26240276
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Systemic Therapy De-Escalation in Early-Stage Triple-Negative Breast Cancer: Dawn of a New Era?
    Gupta RK; Roy AM; Gupta A; Takabe K; Dhakal A; Opyrchal M; Kalinski P; Gandhi S
    Cancers (Basel); 2022 Apr; 14(8):. PubMed ID: 35454764
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.
    von Minckwitz G; Schneeweiss A; Loibl S; Salat C; Denkert C; Rezai M; Blohmer JU; Jackisch C; Paepke S; Gerber B; Zahm DM; Kümmel S; Eidtmann H; Klare P; Huober J; Costa S; Tesch H; Hanusch C; Hilfrich J; Khandan F; Fasching PA; Sinn BV; Engels K; Mehta K; Nekljudova V; Untch M
    Lancet Oncol; 2014 Jun; 15(7):747-56. PubMed ID: 24794243
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Disease-free survival landmark analysis: a potential critical endpoint in triple-negative breast cancer.
    Zheng F; Wei T; Wang X; Du F; Yue J; Yuan P
    Exp Hematol Oncol; 2022 Sep; 11(1):65. PubMed ID: 36167566
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prospective study of cyclophosphamide, thiotepa, carboplatin combined with adoptive DC-CIK followed by metronomic cyclophosphamide therapy as salvage treatment for triple negative metastatic breast cancers patients (aged <45).
    Wang X; Ren J; Zhang J; Yan Y; Jiang N; Yu J; Di L; Song G; Che L; Jia J; Zhou X; Yang H; Lyerly HK
    Clin Transl Oncol; 2016 Jan; 18(1):82-7. PubMed ID: 26266766
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions.
    Goble S; Bear HD
    Surg Clin North Am; 2003 Aug; 83(4):943-71. PubMed ID: 12875604
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chemotherapy for advanced endometrial cancer with carboplatin and epirubicin.
    Tirmazy SH; Barthakur U; El-Modir A; Anwar S; Fernando I
    Anticancer Res; 2014 Jul; 34(7):3793-8. PubMed ID: 24982404
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.